Brook Jennings

Brook leads the Sales and Marketing efforts for Immunology and Inflammation. Since joining Regeneron and the Dupixent Team in 2015, he has guided the Marketing organization through the global launches of the 1st three Dupixent indications - Atopic Dermatitis, Asthma, and Chronic Rhinosinusitis with Nasal Polyps. He later led the U.S. Dermatology Sales and Marketing teams through additional Dupixent launches, including Prurigo Nodularis, Bullous Pemphigoid, and Chronic Spontaneous Urticaria.

Before joining Regeneron, Brook led the Psoriasis franchise for LEO.  In that role, as a key member of both the U.S. and Global Leadership Teams, he directed Sales and Marketing activities for multiple brands, overseeing several product launches and end-of-lifecycle transitions.  Earlier in his career, Brook held global roles at Novartis in Allergy and Immunology. Based in Switzerland, he led the successful Asia/Pacific launch of the Asthma indication for Xolair® and managed its ongoing lifecycle. He subsequently led the global teams through the integration and relaunch of TOBI® for Cystic Fibrosis.

Prior to working abroad, Brook spent a decade at Johnson & Johnson in roles of increasing responsibility across Sales, Sales Leadership, Sales Operations, and Marketing.

He resides in Pennsylvania with his wife, Christine, their son, Walker, and their two Portuguese Water Dogs, Luna and Milo.